Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 69097-937

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 69097-937). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure. (Structure)

Chemical structure of Lurasidone Hydrochloride, illustrating the molecular framework including multiple rings and the hydrochloride component as shown in the diagram.*

FDA Label Image

Lurasidone_fig01. (Lurasidone Fig01)

A clinical pharmacokinetic interaction chart showing fold change and 90% confidence intervals for Cmax and AUC of lurasidone when co-administered with various drugs. The chart compares changes relative to lurasidone alone with strong CYP3A4 inhibitors (Ketoconazole), moderate CYP3A4 inhibitors (Diltiazem), and strong CYP3A4 inducers (Rifampin, Lithium) at specified doses.*

FDA Label Image

Lurasidone_fig02. (Lurasidone Fig02)

A forest plot illustrating the fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, and Ctrough) of various interacting drugs relative to their levels when administered alone. The drugs assessed include Digoxin, Midazolam, Ethinyl Estradiol, Norelgestromin, and Lithium, indicating their interaction profiles with a referencing vertical line at zero change.*

FDA Label Image

Lurasidone_fig03. (Lurasidone Fig03)

A pharmacokinetic chart illustrating fold change and 90% confidence intervals for Lurasidone Hydrochloride. The x-axis represents change relative to reference on a scale from 0 to 6. Data categories include renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population subgroups by gender, race, and Asian ethnicity, showing Cmax and AUC parameters with error bars.*

FDA Label Image

20mg. (20mg)

Lurasidone Hydrochloride Tablets 20 mg film-coated tablet label showing dosage strength and quantity of 30 tablets. The label includes storage instructions, manufacturer details (InveGen Pharmaceuticals, Inc.), and dispensing guidance. Labeler shown as Cipla USA, Inc., with a UPC barcode and a blank area marked 1.0" x 1.3" No Varnish.*

FDA Label Image

40mg. (40mg)

Label for Lurasidone Hydrochloride Tablets, 40 mg strength. The label indicates this is a prescription drug with 30 film-coated tablets per container, distributed by Cipla USA, Inc. Directions specify to dispense the Medication Guide separately to patients. Storage instructions and manufacturer details are included, noting the product is manufactured by InvaGen Pharmaceuticals, a Cipla subsidiary.*

FDA Label Image

60mg. (60mg)

Label for Lurasidone Hydrochloride 60 mg film-coated tablets by Cipla USA, Inc., for oral use. The label indicates prescription use only, contains 30 tablets, and includes dispensing and storage instructions. The label also states the manufacturer as InvaGen Pharmaceuticals, Inc., a Cipla Ltd. subsidiary, with addresses in Hauppauge, NY, and Warren, NJ.*

FDA Label Image

80mg. (80mg)

Lurasidone Hydrochloride Tablets 80 mg film-coated oral tablets label with 30 tablets per package. The label includes storage instructions, pharmacist dispensing guidance, and manufacturer information for Cipla USA, Inc. The label size is indicated as 1.0" x 1.3" with no varnish.*

FDA Label Image

120mg.jpg (120mg)

Label for Lurasidone Hydrochloride Tablets 120 mg film-coated oral tablets by Cipla USA, Inc. The label states the dosage strength, packaging of 30 tablets, and includes storage instructions along with manufacturer information and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.